2024-10-31 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison:**

Pfizer Inc. (PFE) has underperformed the S&P 500 (VOO) significantly. As of today, PFE's cumulative return is -13.18%, while the S&P 500 has yielded 136.74%. This translates to a staggering -149.92% relative underperformance.

**2. Recent Price Movement:**

* **Closing Price:** $28.46 (Last Market: $28.34)
* **5-day Moving Average:** $28.65
* **20-day Moving Average:** $29.02
* **60-day Moving Average:** $29.01

The current price is slightly below the 5-day, 20-day, and 60-day moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 27.06 - This indicates the stock is currently oversold.
* **PPO:** -0.27 - This suggests the stock is in a downward trend.
* **Delta_Previous_Relative_Divergence:** -1.43 - This indicates a short-term downtrend in relative strength.
* **Expected Return:** 0.0% - Over the long term (2 years or more), PFE is expected to deliver an average return similar to the S&P 500.

**4. Recent Earnings Performance:**

| Date       | EPS     | Expected EPS |
|------------|---------|---------------|
| 2024-10-29 | 1.06    | 0.614         |
| 2024-07-30 | 0.6     | 0.458         |
| 2024-05-01 | 0.82    | 0.516         |
| 2024-01-30 | 0.1     | -0.19          |
| 2023-10-31 | -0.17   | -0.32          |

Pfizer has consistently surpassed earnings expectations in recent quarters. The latest quarter's EPS of 1.06 is significantly higher than the anticipated 0.614, demonstrating positive growth momentum.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue      | Profit Margin |
|-------------|--------------|---------------|
| 2024-06-30 | $13.28B      | 75.16%        |
| 2024-03-31 | $14.88B      | 77.29%        |
| 2023-12-31 | $14.25B      | 46.92%        |
| 2023-09-30 | $13.23B      | 29.95%        |
| 2023-06-30 | $13.01B      | 75.11%        |

Pfizer's revenue has remained consistently high, indicating a robust business model. Profit margins have been volatile, but they are generally high, indicating the company's profitability.

**2) Capital and Profitability:**

| Quarter     | Equity     | ROE       |
|-------------|------------|-----------|
| 2024-06-30 | $87.70B    | 0.05%     |
| 2024-03-31 | $92.28B    | 3.38%     |
| 2023-12-31 | $89.01B    | -3.78%    |
| 2023-09-30 | $96.93B    | -2.46%    |
| 2023-06-30 | $99.02B    | 2.35%     |

Pfizer's equity has been relatively stable, and ROE has fluctuated. The recent decline in ROE in Q4 2023 might be due to factors such as increased expenses or lower profitability.

**6. News and Recent Issues:**

* **Recent Earnings Release:** Pfizer's recent earnings release highlighted strong performance and beat expectations. The company also announced positive developments in its drug pipeline and reiterated its commitment to research and development.
* **Market Outlook:** Analysts remain optimistic about Pfizer's long-term prospects due to its robust revenue stream, strong brand recognition, and ongoing innovation. However, some analysts are concerned about the potential impact of competition and declining sales of its COVID-19 vaccine.

**7. Overall Analysis:**

Pfizer is a pharmaceutical giant with a strong track record of profitability. Its recent earnings performance has been positive, and its financials remain strong. However, the stock has been underperforming the market, and its valuation is relatively high. Investors looking for short-term gains might want to avoid PFE at this time, but those with a long-term investment horizon may find it an attractive option, given its robust fundamentals and potential for future growth.

**8. Key Points Summary:**

* PFE is significantly underperforming the S&P 500.
* Recent price movement suggests a short-term downtrend.
* Technical indicators signal oversold conditions and a downward trend.
* Strong earnings performance and robust financials suggest positive long-term prospects.
* Market sentiment remains optimistic, but competition and declining COVID-19 vaccine sales are concerns.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.
